18F-Fluoromisonidazole PET in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease Presenting With Tumefactive Demyelinating Lesion. (May 2021)

• Record Type: Journal Article
• Authors: Mitamura, Katsuya; Norikane, Takashi; Takata, Tadayuki; Yamamoto, Yuka; Nishiyama, Yoshihiro
• Is Part Of: Clinical nuclear medicine. Volume 46:Number 5(2021)
• Publication Date: 2021-05
• Subjects: demyelinating lesion -- FMISO -- MOG antibody–associated disease -- PET; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000003429
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: Tumefactive demyelinating lesions have been appreciated as part of the clinical and radiological spectrum of myelin oligodendrocyte glycoprotein antibody–associated disease. A 63-year-old woman was followed up for myelin oligodendrocyte glycoprotein antibody–associated disease. Two years later, she presented with right facial paralysis. T2-weighted MRI scan demonstrated a high-signal-intensity area with edematous change in the right frontal lobe, and partial enhancement was shown on contrast-enhanced T1-weighted image. This contrast-enhanced area showed increased 18 F-fluoromisonidazole uptake.